Fulgent Genetics(NASDAQ) FLGT

Current Price$19.63

Market Cap$558.64M

Since IPO (2016)+114%

5 Year-78%

1 Year+7%

1 Month+3%

Fulgent Genetics last closing stock price
Metric	Price	Date
Last close	USD 19.67	2026-07-24

Fulgent Genetics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-2.43%	USD 20.16	2026-07-17
1 month	+2.82%	USD 19.13	2026-06-24
3 month	+20.6%	USD 16.31	2026-04-24
Year to date	-25.12%	USD 26.27	2025-12-31
1 year	+6.84%	USD 18.41	2025-07-24
3 year	-50.2%	USD 39.50	2023-07-25
5 year	-78.02%	USD 89.50	2021-07-23
Since inception	+114.27%	USD 9.18	2016-09-29

Fulgent Genetics Financials at a Glance

Market Cap

$558.64M

Revenue (TTM)

$320.35M

Net Income (TTM)

-$73.81M

EPS (TTM)

-$2.40

P/E Ratio

-8.21

Dividend

$0.00

Beta (Volatility)

0.98 (Low)

Dividend

$0.00

Beta (Volatility)

0.98 (Low)

Price

$19.63

Volume

145,673.587

Open

$19.98

Price

$19.63

Volume

145,673.587

Open

$19.98

Previous Close

$19.67

Daily Range

$19.58 - $20.14

52-Week Range

$13.46 - $31.04

Estimated Earnings Date

Jul 30, 2026

Dividend

$0.00

Beta (Volatility)

0.98 (Low)

Price

$19.63

Volume

145,673.587

Open

$19.98

Previous Close

$19.67

Daily Range

$19.58 - $20.14

52-Week Range

$13.46 - $31.04

Estimated Earnings Date

Jul 30, 2026

FLGT News

Page 1

FLGT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Fulgent Genetics

Fulgent helps doctors find health issues through medical tests. These tests look at genes to identify specific disease risks. The company also creates new medicines to treat cancer.

What Does Fulgent Provide?

Precision Diagnostics: Genomic tests that identify inherited conditions and cancer risks; generated $40.2 million in revenue during the first quarter of 2026.
Anatomic Pathology: Specialized laboratory services for analyzing skin and tumor tissue; contributed $25.1 million in revenue for early 2026.
BioPharma Services: Research and testing support for drug development projects; accounted for $5.8 million in revenue in the first quarter of 2026.
Therapeutic Development: Pharmaceutical research focusing on targeted cancer treatments using a proprietary drug delivery platform.

Strategic Growth and Acquisitions

Acquired Bako Diagnostics and StrataDx on March 17, 2026, to expand its pathology laboratory services and national sales team.
Purchased ANP Technologies, Inc. on July 9, 2025, to secure full ownership of patents used in clinical drug studies.
Established a strategic partnership with Helio Health, Inc. to commercialize blood-based tests for early cancer detection.
Repurchased 2.6 million shares of common stock for $40.1 million during the first quarter of 2026.

High Volume and Targeted Tech

Fulgent combines high-capacity genetic testing with internal drug development to create an integrated healthcare business. Its technology platform aims to improve how drugs target cancer while reducing side effects for patients.

Financial Performance Highlights

Revenue reached $71.1 million in the first quarter of 2026, down 3.2% from $73.5 million year-over-year.
Gross profit reached $21.5 million in the first quarter of 2026, down 24% from $28.3 million in early 2025.
Operating loss was $34.6 million in early 2026, which deepened from a loss of $19.8 million in the prior year period.
Net loss hit $24.8 million in the first quarter of 2026, worsening from a loss of $11.5 million year-over-year.

Bottom Line

Fulgent is evolving from a diagnostic laboratory into a broader precision medicine and drug development firm. Recent acquisitions in pathology and oncology have expanded its technical capabilities and commercial footprint.

AI Generated • May 7, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

Employees

1,344

CEO

Ming Hsieh

Website

www.fulgentgenetics.com

Headquarters

El Monte, CA 91780, US

FLGT Financials

Key Financial Metrics (TTM)

Gross Margin

38.71%

Operating Margin

-33.07%

Net Income Margin

-23.04%

Return on Equity

-6.70%

Return on Capital

-8.14%

Return on Assets

-6.38%

Earnings Yield

-12.18%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$558.64M

Shares Outstanding

28.40M

Volume

145.67K

Avg. Volume

432.33K

Financials (TTM)

Gross Profit

$124.02M

Operating Income

-$105.92M

EBITDA

-$58.51M

Operating Cash Flow

-$90.11M

Capital Expenditure

-$23.06M

Free Cash Flow

-$113.17M

Cash & ST Invst.

$276.30M

Total Debt

$10.17M

Fulgent Genetics Performance Analysis

Fulgent Genetics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 618,968,000	-37.6%
2023	2023-12-31	USD 289,213,000	-53.3%
2024	2024-12-31	USD 283,470,000	-2.0%
2025	2025-12-31	USD 322,671,000	13.8%

Fulgent Genetics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	11.4%
Q3	2025-09-30	2.8%
Q4	2025-12-31	-0.9%
Q1	2026-03-31	-14.6%

Fulgent Genetics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD 4.63	-71.5%
2023	2023-12-31	USD -5.63	N/A
2024	2024-12-31	USD -1.41	-74.9%
2025	2025-12-31	USD -1.97	39.2%

Fulgent Genetics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-64.9%
Q3	2025-09-30	65.6%
Q4	2025-12-31	-261.9%
Q1	2026-03-31	-5.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$71.14M

-3.2%

Gross Profit

$21.49M

-24.2%

Gross Margin

30.21%

N/A

Market Cap

$558.64M

N/A

Market Cap/Employee

$425.47K

N/A

Employees

1,313

N/A

Net Income

-$24.83M

-115.3%

EBITDA

-$19.96M

-244.7%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$276.30M

-13.7%

Total Debt

$10.17M

+32.8%

Accounts Receivable

$75.74M

-5.8%

Inventory

$770.00K

-91.1%

Long Term Debt

$7.48M

+27.9%

Short Term Debt

$2.69M

+48.7%

Return on Assets

-6.38%

N/A

Return on Invested Capital

-9.93%

N/A

Free Cash Flow

$1.90M

+120.7%

Operating Cash Flow

$7.10M

+260.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

MYGNMyriad Genetics, Inc.

MYGNMyriad Genetics, Inc.$5.61-1.58%

ARVNArvinas, Inc.

ARVNArvinas, Inc.$8.03-1.11%

VALNValneva SE

VALNValneva SE$4.78+0.00%

PACBPacific Biosciences of California, Inc.

PACBPacific Biosciences of California, Inc.$1.36-2.86%

CSTLCastle Biosciences, Inc.

CSTLCastle Biosciences, Inc.$24.69-3.12%

AVXLAnavex Life Sciences Corp.

AVXLAnavex Life Sciences Corp.$2.40-3.23%

DRIODarioHealth Corp.

DRIODarioHealth Corp.$7.79+4.28%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.42-0.04%

ONDSOndas

ONDSOndas$7.80-0.02%

SOFISoFi Technologies

SOFISoFi Technologies$16.46-0.01%

FFord Motor Company

FFord Motor Company$14.37+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.48+0.07%

CLFCleveland-Cliffs

CLFCleveland-Cliffs$11.93+0.09%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$64.00-0.03%

Questions About FLGT

What is the current price of Fulgent Genetics?

Fulgent Genetics is trading at $19.67 per share.

What is the 52-week range for Fulgent Genetics?

Over the past 52 weeks, Fulgent Genetics has traded between $13.46 and $31.04.

How much debt does Fulgent Genetics have?

As of the most recent reporting period, Fulgent Genetics reported total debt of $10.17M.

How much cash does Fulgent Genetics have on hand?

Fulgent Genetics reported $23.40M in cash and cash equivalents in its most recent financial results.

What is Fulgent Genetics’s dividend yield?

Fulgent Genetics does not currently have a dividend yield.

Fulgent Genetics(NASDAQ) FLGT

Fulgent Genetics Financials at a Glance

FLGT News

Fulgent Genetics: A Risky Bet or a Hidden Gem?

Fulgent (FLGT) Q2 Revenue Jumps 16%

Why Fulgent Genetics Stock Was Crushing It on Friday

Investing in Genetic Testing Stocks

Fulgent Genetics Revenue Tops Estimates

Fulgent Genetics: EPS Exceeds Forecast

Fulgent Genetics Q2: Core Revenue Grows, but Profitability Is Still an Issue

Got $2,500? This Dirt Cheap Growth Stock Could Be Worth Buying Hand Over Fist

FLGT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Fulgent Genetics

What Does Fulgent Provide?

Strategic Growth and Acquisitions

High Volume and Targeted Tech

Financial Performance Highlights

Bottom Line

FLGT Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Fulgent Genetics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About FLGT

What is the current price of Fulgent Genetics?

What is the 52-week range for Fulgent Genetics?

How much debt does Fulgent Genetics have?

How much cash does Fulgent Genetics have on hand?

What is Fulgent Genetics’s dividend yield?

Premium Investing Services